XML 51 R42.htm IDEA: XBRL DOCUMENT v3.23.1
REVENUE Disaggregated Revenue Table (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Disaggregation of Revenue [Line Items]      
Accounts Receivable, Allowance for Credit Loss $ 52.8   $ 43.5
Unbilled Services, Allowance for Credit Loss 10.8   10.5
Note Receivable, Allowance for Credit Loss 0.7   0.7
Allowance for Credit Loss 64.3   54.7
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings 11.1    
Allowance for Credit Loss, Write Off 1.5    
Deferred Revenue, Revenue Recognized 165.3 $ 163.8  
Contract with Customer, Asset, before Allowance for Credit Loss 715.9   805.9
Revenue, Remaining Performance Obligation, Amount $ 4,720.0    
Long Term Contracts Duration Minimum 1 year    
Long Term Contracts Duration Maximum 8 years    
Contract with Customer, Performance Obligation Satisfied in Previous Period $ 10.4 31.7  
Contract with Customer, Liability 586.7   582.1
Capitalized Contract Cost, Amortization 2.4 3.1  
Accrued Sales Commission 38.3   38.2
Capitalized Contract Cost, Net 14.3   15.0
Amount of Deferred Costs Related to Long-term Contracts 52.6   53.2
Amortization of Deferred Sales Commissions 8.4 $ 7.2  
Unbilled Contracts Receivable $ 705.1   795.4
Percent of Revenue Contributed 100.00% 100.00%  
Revenues $ 3,777.9 $ 3,899.6  
Accounts Receivable, after Allowance for Credit Loss, Current 2,344.8   2,222.0
Allowance for Credit Loss, Receivable, Other, Current (10.8)   (10.5)
Contract with Customer, Asset, after Allowance for Credit Loss, Current $ 705.1   795.4
Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 12.00% 13.00%  
North America      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 81.00% 80.00%  
Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 7.00% 7.00%  
UNITED STATES      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 78.30% 76.90%  
Revenues $ 2,959.2 $ 3,000.5  
Medicare and Medicaid [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 7.00% 6.00%  
LabCorp Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 63.00% 63.00%  
LabCorp Diagnostics [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | North America      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 63.00% 63.00%  
LabCorp Diagnostics [Member] | Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Client [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 17.00% 17.00%  
LabCorp Diagnostics [Member] | Client [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Client [Member] | North America      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 17.00% 17.00%  
LabCorp Diagnostics [Member] | Client [Member] | Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 8.00% 5.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member] | North America      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 8.00% 5.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member] | Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | North America      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 7.00% 6.00%  
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Third party [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 31.00% 35.00%  
LabCorp Diagnostics [Member] | Third party [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Third party [Member] | North America      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 31.00% 35.00%  
LabCorp Diagnostics [Member] | Third party [Member] | Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed   37.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed   13.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | North America      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed   17.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed   7.00%  
Diagnostics      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 63.00%    
Accounts Receivable, before Allowance for Credit Loss $ 1,131.6   1,046.9
Drug Development      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 37.00%    
Accounts Receivable, before Allowance for Credit Loss $ 1,266.0   $ 1,218.6
Drug Development | Biopharmaceutical and medical device companies [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 37.00%    
Drug Development | Biopharmaceutical and medical device companies [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 12.00%    
Drug Development | Biopharmaceutical and medical device companies [Member] | North America      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 18.00%    
Drug Development | Biopharmaceutical and medical device companies [Member] | Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 7.00%    
Notes Receivable [Member]      
Disaggregation of Revenue [Line Items]      
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings $ 0.0    
Allowance for Credit Loss, Write Off 0.0    
Unbilled Contracts Receivable [Member]      
Disaggregation of Revenue [Line Items]      
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings 0.0    
Allowance for Credit Loss, Write Off 0.3    
Accounts Receivable [Member]      
Disaggregation of Revenue [Line Items]      
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings 11.1    
Allowance for Credit Loss, Write Off $ 1.8